Gateway to Translation Webinar: Regen CTC
The “Gateway to Translation” (G2T) webinar series is a joint initiative between the University of Cambridge (Cambridge Academy of Therapeutic Sciences, CATS) and the University of Manchester (Translation Manchester).
The aim of these monthly webinars is to stimulate the translation of research into the clinics by educating academics about trends, technologies and research in the commercial sphere and by facilitating collaborations between academia and the medtech, biotech and pharma industry sectors. Recordings from previous webinars are available here.
Dr. Zoe Hewitt, Co-Founder and CEO of Regen CTC Limited
The February 2025 webinar of this series, hosted by Translation Manchester, was on Wednesday 26th February, from 2-3pm (via Zoom). Our guest speaker was Dr. Zoe Hewitt, Co-Founder and CEO of Regenerative Cell Therapy Consulting (Regen CTC) Limited, a network of UK academic experts with real world experience of translating human pluripotent stem cell (hPSC)-derived cell therapies to the clinic. Dr. Hewitt delivered a talk on the topic of “Translating Cell and Gene Therapies to the Clinic: Common Challenges and Potential Solutions”. The session was chaired by Dr. Stuart Ellison, Research Fellow at The University of Manchester. This webinar provided attendees with insights into the complexities of translating cell and gene therapies to the clinic, emphasising the importance of early regulatory engagement, quality management, and strategic planning for commercialisation.
Topic: “Translating Cell and Gene Therapies to the Clinic: Common Challenges and Potential Solutions”
Guest Speaker: Dr. Zoe Hewitt, Co-Founder and CEO of Regenerative Cell Therapy Consulting (Regen CTC) Ltd.
Date and Time: Wednesday 26th February, from 2-3pm
The webinar was chaired by Dr Stuart Ellison, Research Fellow at the University of Manchester and recipient of one of Translation Manchester’s pump priming awards.
Click to learn more about the speaker
Dr. Zoe Hewitt has a background in Pluripotent Stem Cells, which started in 2001 when she obtained her PhD from the Roslin Institute/University of Edinburgh. After completing her studies, she worked with a team developing differentiation protocols for hepatocytes, before moving to the University of Sheffield in 2006, where she established and managed a clean room facility responsible for deriving the UK’s first clinically available human Embryonic Stem Cells (MasterShef lines 1 to 14). Within this facility, Zoe and her team delivered the starting master cell banks (Shef1) for the London Project to Cure Blindness, resulting in the first successful UK clinical trial of an hPSC-derived retinal pigment epithelium (RPE) cell replacement therapy.
In 2015, Zoe transitioned from active research to become a Project Manager for the UK Regenerative Medicine Platform (UKRMP), initially for the Pluripotent Stem Cell Platform (PSCP), winning the UKRMP Special Merit Award in 2017, and then for the Pluripotent Stem Cell and Engineered Cell (PSEC) Hub. The goal of the UKRMP Hubs was to advance regenerative medicine therapies by addressing the rate-limiting steps of hPSC-based cell replacement therapies to enable clinical delivery and commercial development. As part of the sustainability strategy for UKRMP, Zoe co-founded Regenerative Cell Therapy Consulting Limited in May 2022, aiming to assist innovative research in translating from laboratory research to commercial development and investment.
Click to Learn More about the Company
Regen CTC’s network includes fundamental scientists, manufacturing engineers, clinicians, and expert translational scientists with real-world experience. They have extensive experience in developing quality management systems, clean room operations, and process development of research protocols. Further information can be found on the Regen CTC website.
Watch a recording from the event below:
Contact Us
Email:
0 Comments